van Domburg R T, Foley D P, Breeman A, van Herwerden L A, Serruys P W
Thoraxcenter, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
Eur Heart J. 2002 Apr;23(7):543-9. doi: 10.1053/euhj.2001.2821.
The purpose of this study is to compare the long-term outcome (up to 20 years) of coronary artery bypass surgery (CABG) with percutaneous transluminal coronary angioplasty (PTCA) in a consecutive patient series at a single centre. Survival is similar after CABG and PTCA up to 8 years follow-up in patients with multivessel disease, with a reduced need for repeat revascularization after CABG. As coronary artery disease is a lifetime disease, longer-term follow-up of these revascularization therapies is necessary to help clinical decision-making.
The CABG study population consisted of the first 1041 consecutive patients who underwent a first elective coronary bypass surgery between 1970 and 1980. The PTCA study population consisted of 702 consecutive patients who underwent a first elective coronary angioplasty procedure between 1980 and 1985. Mortality and subsequent revascularization up to 20 years were captured. Survival rates were adjusted using proportional hazards methods to account for baseline differences.
The unadjusted survival rates were 92%, 77%, 57% and 49% after CABG at respectively, 5-, 10-, 15- and 17 years and 91%, 80%, 64% and 59% after PTCA. In the multivessel disease subgroup, survival was similar with a benefit apparent after CABG in the first 8 years of follow-up. The therapy chosen, CABG or PTCA, was a univariate predictor of mortality in favour of PTCA (RR: 1.28; 95% CI: 1.10-1.49), but after correction for baseline characteristics, the relative risk of mortality for CABG vs PTCA was comparable (RR: 1.03; 95% CI: 0.87-1.24). The adjusted survival curves in the subgroup of diabetic elderly patients with multivessel disease were similar after the tenth year with only a slightly better survival in the CABG population in the first 10 years. Repeat intervention was more frequently required after PTCA during the first 8 years, but after this time more frequently in the CABG group.
When comparing CABG and PTCA it can be concluded that both strategies are equally effective in terms of 20-year survival. In particular, after more than 10 years all differences tend to disappear. While repeat intervention was significantly higher in the first year after PTCA, after 7-8 years, reintervention was greater in patients who had initial CABG.
本研究旨在比较单中心连续患者队列中冠状动脉旁路移植术(CABG)与经皮腔内冠状动脉成形术(PTCA)的长期疗效(长达20年)。在多支血管病变患者中,CABG和PTCA术后长达8年的随访中生存率相似,CABG术后再次血运重建的需求减少。由于冠状动脉疾病是一种终身疾病,对这些血运重建治疗进行长期随访对于临床决策很有必要。
CABG研究人群包括1970年至1980年间连续接受首次择期冠状动脉旁路手术的前1041例患者。PTCA研究人群包括1980年至1985年间连续接受首次择期冠状动脉成形术的702例患者。记录了长达20年的死亡率和随后的血运重建情况。使用比例风险方法调整生存率以考虑基线差异。
CABG术后5年、10年、15年和17年的未调整生存率分别为92%、77%、57%和49%,PTCA术后分别为91%、80%、64%和59%。在多支血管病变亚组中,生存率相似,在随访的前8年CABG术后有明显益处。所选择的治疗方法,即CABG或PTCA,是死亡率的单变量预测因素,倾向于PTCA(RR:1.28;95%CI:1.10 - 1.49),但在校正基线特征后,CABG与PTCA的相对死亡风险相当(RR:1.03;95%CI:0.87 - 1.24)。在多支血管病变的老年糖尿病患者亚组中,调整后的生存曲线在第10年后相似,仅在CABG人群的前10年中生存率略高。在最初的8年中,PTCA术后更频繁需要重复干预,但此后CABG组更频繁。
比较CABG和PTCA时,可以得出结论,就20年生存率而言,两种策略同样有效。特别是,10多年后所有差异趋于消失。虽然PTCA术后第一年重复干预明显更高,但7 - 8年后,初始接受CABG的患者再次干预更多。